Composition, form of production and packaging
? Tablets, coated with a coating from yellow to orange, are round; the core of the tablet is orange.
1 tab.
Tilorone dihydrochloride 125 mg
Excipients: magnesium hydroxycarbonate (magnesium carbonate heavy) - 69 mg, povidone K30 - 4 mg, calcium stearate - 2 mg.
Sheath composition: sucrose 158.11 mg, povidone K17 5.65 mg, copovidone 0.44 mg, magnesium hydroxycarbonate (magnesium carbonate light) 25.7 mg, titanium dioxide 1.2 mg, silicon dioxide colloid (aerosil A-380) 1 mg, dye quinoline yellow 0.09 mg, dye sunset yellow 0.01 mg, macrogol 6000-6 mg, beeswax 0.15 mg, paraffin liquid 0.15 mg, talc 1.5 mg.
3 pcs. - packings of cellular contour (1) - packs cardboard.
3 pcs. - packings cellular planimetric (2) - packs cardboard.
4 things. - packings of cellular contour (1) - packs cardboard.
4 things. - packings cellular planimetric (2) - packs cardboard.
6 pcs. - packings of cellular contour (1) - packs cardboard.
6 pcs. - packings cellular planimetric (2) - packs cardboard.
10 pieces. - packings of cellular contour (1) - packs cardboard.
10 pieces. - packings cellular planimetric (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2014.
PHARMACHOLOGIC EFFECT
Antiviral and immunomodulating drug. Lavomax В® stimulates the formation of? -,? -,? -terferons. In response to the introduction of Lavomax, interferon is produced mainly by cells of the intestinal epithelium, hepatocytes, T-lymphocytes and neutrophils.
After taking the drug inside, the maximum production of interferon is determined in the intestine-liver-blood sequence after 4-24 hours. Lavomax В® has an immunomodulatory and antiviral effect. Stimulates bone marrow stem cells, depending on the dose, enhances antibody formation, reduces the degree of immunosuppression, restores the ratio of T-help / T-suppressors.
Effective against various viral infections, incl. against influenza viruses, other acute respiratory viral infections, hepatitis and herpes viruses, cytomegaloviruses and neurotropic viruses.
The mechanism of antiviral action is associated with the inhibition of translation of virus-specific proteins in infected cells, as a result of which the reproduction of viruses is suppressed.
PHARMACOKINETICS
Suction
After taking the drug inside Tyloron is quickly absorbed from the digestive tract. Bioavailability is 60%.
Distribution
Binding to plasma proteins is about 80%.
Metabolism and excretion
Tyloron does not undergo biotransformation and does not accumulate in the body. It is excreted almost unchanged with feces (about 70%) and urine (about 9%). T 1/2is 48 hours.
INDICATIONS
The drug is used in adults as part of complex therapy:
- viral hepatitis A, B and C;
- herpetic infection;
- cytomegalovirus infection;
- infectious-allergic and viral encephalomyelitis;
- urogenital and respiratory chlamydia;
- non-gonococcal urethritis;
- pulmonary tuberculosis.
Treatment and prevention of influenza and other acute respiratory viral infections.
DOSING MODE
The drug is taken orally after a meal.
In the treatment of influenza and other acute respiratory viral infections - in the first two days of the disease - 125 mg, then - every other day, 125 mg. The course dose is 750 mg (for the course of treatment 6 tablets for 125 mg).
For the prevention of influenza and other acute respiratory viral infections - 125 mg once a week for 6 weeks. The course of treatment - 6 tablets. for 125 mg.
For the treatment of viral hepatitis A - the first day of 125 mg 2 times, then - 125 mg every other day. The course dose is 1.25 g (for the course of treatment - 10 tablets for 125 mg).
For the treatment of acute hepatitis B - the first and second days of 125 mg, then - 125 mg every other day. The course dose is 2 g (for the course of treatment - 16 tablets for 125 mg), with prolonged course of hepatitis B - 125 mg 2 times / day on the first day, then - 125 mg every other day. The course dose is 2.5 g (for the course of treatment - 20 tablets for 125 mg).
In chronic hepatitis B - the initial phase of treatment (2.5 g) - the first two days of 250 mg, then - 125 mg every other day. The continuation phase (from 1.25 g to 2.5 g) is 125 mg per week. The course dose of Lavomax В® from 3.75 to 5 g (for treatment course - from 30 to 40 tablets per 125 mg), the duration of therapy is 3.5-6 months, depending on the results of biochemical, immunological, morphological studies reflecting the degree of activity of the process.
In acute hepatitis C - the first and second days of 125 mg, then - 125 mg every other day. The course dose is 2.5 g (for the course of treatment - 20 tablets for 125 mg).
In chronic hepatitis C - the initial phase of treatment (2.5 g) - the first two days of 250 mg, then - 125 mg every other day. The continuation phase (2.5 g) is 125 mg per week. The course dose of the drug Lavomax В® - 5 g (for treatment - 40 tablets for 125 mg). The duration of therapy is 6 months, depending on the results of biochemical, immunological, and morphological markers of the activity of the process.
To treat herpetic, cytomegalovirus infection - the first two days of 125 mg, then - every other day, 125 mg. The course dose is 2.5 g (for the course of treatment - 20 tablets for 125 mg).
With urogenital and respiratory chlamydia, non-gonococcal urethritis - the first two days of 125 mg, then - every other day, 125 mg. The course dose is 1.25 g (for the course of treatment - 10 tablets for 125 mg).
In the complex therapy of pulmonary tuberculosis - the first two days of 250 mg, then - 125 mg every other day. The course dose is 2.5 g (for the course of treatment - 20 tablets for 125 mg).
In the complex treatment of neuroviral infections, the dose is set individually, the course of treatment is 4 weeks.
SIDE EFFECT
Possible: short-term chills, allergic reactions, symptoms of dyspepsia.
CONTRAINDICATIONS
- Pregnancy;
- lactation period (breastfeeding);
- children and adolescence under 18;
- deficiency of sugar / isomaltase, intolerance to fructose, glucose-galactose malabsorption (the preparation contains sucrose);
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
Lavomax В® is contraindicated in pregnancy and lactation (breastfeeding).
APPLICATION FOR CHILDREN
Contraindicated in children and adolescents under 18 years.
SPECIAL INSTRUCTIONS
Impact on the ability to drive vehicles and manage mechanisms
The use of the drug does not affect the ability to drive vehicles and engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
OVERDOSE
Cases of overdose of Lavomax В® are unknown.
DRUG INTERACTION
Clinically significant interaction of the drug Lavomax В® with antibiotics, standard therapy of viral and bacterial diseases, alcohol was not detected.
Compatible with antibiotics and standard means of treatment of viral and bacterial diseases.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
The drug should be stored out of reach of children, dry, protected from light at a temperature of no higher than 25 В° C. Shelf life - 2 years.
